I’m honestly a little surprised by the sparsity of examples? One example of improving an existing therapeutic (Generate Biomedicines), one example of speeding up an existing clever play in food allergies (Divergence Labs), one fairly generic lead optimization play, and then we get … Claude helped write better paperwork and documentation for Enveda?!

I know Anthropic are brilliant at knowing when to focus where, but I genuinely expected them to be talking about 3-5x more serious scaled up drug discovery plays at this stage.

Is this not a focus, or did the big plays not want to be part of a roundup post?